Free Neurology CME

  • FREE

    CME: Advanced prostate cancer: optimizing management strategies

    Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.

    By the end of the session the participant will be able to:

    • Recall the pathophysiology of aPC in a manner that informs treatment mechanisms
    • Describe differences in approach between hormone-sensitive and castration-resistant aPC
    • Identify the treatment modalities currently available for management of aPC and apply them to patient cases using evidence-based medicine
    • Describe emerging treatment options presently available for aPC, their mechanisms of action and safety, and anticipated place in therapy
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/13/2020
    • Expiration of CME credit: 3/13/2021
  • FREE

    CME: Updates in the management of insomnia: therapeutic updates and optimizing treatment

    Insomnia is defined by the dissatisfaction of sleep quality or quantity characterized by having difficulty falling asleep, staying asleep, waking too early, or a combination of these. It is defined as chronic if the condition persists for three months, despite the opportunity for sleep or eradication of external stimulus. Insomnia affects people of all ages, though the likelihood of developing insomnia increases with age: reporting one-third of the adult population having been affected by at least one symptom of insomnia.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of insomnia such that it might inform treatment mechanisms
    • Identify the currently available and emerging pharmacotherapeutic treatments for management of insomnia and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with insomnia to optimize safety and efficacy, suggesting modifications for improvement
    • Describe barriers to care associated with treating patients with insomnia

    Target Audience: The following HCPs: neurologists, psychiatrists, sleep medicine specialists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with insomnia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/18/2019
    • Expiration of CME credit: 10/18/2021
  • FREE

    CME: Parkinson’s disease: optimizing pharmacotherapeutic management strategies and addressing clinical challenges

    Parkinson’s disease (PD), a central nervous system disease of the autonomic and basal ganglia, neocortex, and spinal cord, is thought to affect about one million people in the United States. Its etiology is thought to include a confluence of factors including age, genetic predisposition, comorbid disease states (e.g., Gaucher’s disease), and environmental factor dynamics. Present in 1% of people over age 65 and 2.5% of those older than 80, its symptoms are the direct result of dopaminergic neuronal degradation along the nigrostriatal tract and include bradykinesia, resting tremor, muscle rigidity, and gait disturbance.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology and disease progression of PD and their impact on patient quality-of-life
    • Describe the common clinical presentation(s) of PD
    • Apply recent biomedical literature to the management of PD the primary disease, levodopa-related fluctuations in motor function and dyskinesia, and other disease complications and effects impacting quality-of-life
    • Identify the advances in the biomedical literature concerning PD and emerging treatment options
    • List challenges and barriers to care associated with treating patients with PD

    Target Audience:

    The following healthcare professionals: neurologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in neurology; and any other healthcare professionals with an interest in or who clinically encounter patients with PD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 7/6/19
    • Expiration of CME credit: 7/6/21
  • FREE

    CME: Advanced Prostate Cancer (aPC): Therapeutic Updates, Best Practices, and Emerging Treatments

    Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of aPC
    • Identify the present treatment options currently available for management of aPC
    • Evaluate the safety and effectiveness of certain treatment options in specific patient populations and apply this knowledge to patient cases using evidence-based medicine
    • Describe complications associated with prostate cancer and its treatment (bone, cardiovascular, and endocrinologic risk factors) and develop risk mitigation and optimization strategies

    Target Audience:

    The following HCPs: oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and any other HCPs with an interest in or who may clinically encounter patients with aPC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 5/19
    • Expiration of CME credit: 5/21
  • FREE

    CME: Gaucher disease: Updates from recent research findings

    Gaucher disease (GD) is characterized by a deficiency of the lysosomal enzyme glucocerebrosidase, resulting in the accumulation of sphingolipids throughout the body but most manifesting prominently in the bones. GD is subcategorized based on clinical features: type 1 GD is the non-neuronopathic form and affects mainly the inner organs, while types 2 and 3 are the acute and sub-acute neuropathic forms, whose pathology manifests predominantly within central nervous system. GD impacts about 1 in 75,000 births, making it one of the most common lysosomal storage diseases. One of the first of GD’s complications is the chronic anemia and a persistent bleeding risk. Another is the hepatosplenomegaly, which may be a part of the initial clinical presentation, as may the anatomical abnormalities of bone deformities and stunted growth.

    By the end of the session the participant will be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Gaucher disease including updated recently presented material
    • Describe principles and problems regarding screening for and diagnosing Gaucher disease that can applied to patient cases
    • Describe emerging therapies for Gaucher disease based on research recently presented
    • Design and implement appropriate therapeutic plans for treatment of Gaucher disease based on research recently presented

    Target Audience:

    The following healthcare professionals: pediatricians, neurologists, endocrinologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Gaucher disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 4/28/19
    • Expiration of CME credit: 4/28/21